Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025Blood

Lymphocyte kinetics as a predictor of clinical outcomes following CAR-T therapy for non-Hodgkin lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

HGHelen GandlerARAnirudh RaoYSYuliya Shestovska

Discussion

Loading...

Member takes

Overview

Retrospective analysis links lymphocyte dynamics and clinical outcomes in non-Hodgkin lymphoma CAR-T therapy, suggesting immune status as a key indicator.

Key Points

  • Overall survival improved significantly for patients with higher absolute lymphocyte counts at leukapheresis, indicating immune status influences progression-free survival.
  • A median progression-free survival of 34.5 months was associated with a higher rate of ALC expansion in the first 10 days after CAR-T infusion.
  • Observational analysis defined lymphocyte kinetics metrics, such as peak ALC and AUC for ALC, to assess outcomes following axi-cel therapy.
  • Further investigation of ALC as a dynamic biomarker is warranted based on notable correlations with clinical outcomes in this cohort.

Cite This Study

Gandler et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d4eahttps://doi.org/10.1182/blood-2025-5506
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Absolute lymphocyte count is predictive of response to salvage therapies for post-CAR T failure2025
  2. 2Prognostic impact of CAR-T cell expansion and PD1 expression in patients with DLBCL treated with axicabtagene ciloleucel2025
  3. 3Circulating CD161high CD8 T cells at leukapheresis are associated with reduced risk of progression at 12 months (PFS12) in large B-cell lymphoma treated by axicabtagene ciloleucel: Results from the Phase 2 alycante study (LYSA)2025
  4. 4Longitudinal immune monitoring in patients treated with CD19 and BCMA CAR-T cells using standardized 8‑color flow cytometry panel reveals substantial differences among products kinetics and persistence2025 · 1 citations
  5. 5The simple c-reactive protein (CRP) to albumin ratio (CAR) stratifies treatment response and survival following chimeric antigen receptor T-cell therapy for non-Hodgkin's lymphoma2025